Incyte (INCY) EVP Trotta receives 8,542 stock options grant

Rhea-AI Filing Summary

Incyte Corporation executive Matteo Trotta, EVP and GM of Dermatology US, reported a grant of employee stock options on common stock. On January 16, 2026, he received 8,542 stock options with an exercise price of $106.21 per share and no cost for the option grant itself. These options expire on January 15, 2036.

Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining options vesting monthly over the following three years. After this grant, Trotta beneficially owns 8,542 derivative securities directly in the form of these options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Trotta Matteo

Role EVP, GM, Dermatology US

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	8,542	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 8,542 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trotta Matteo

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DE 19803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GM, Dermatology US

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$106.21	01/16/2026		A		8,542		(1)	01/15/2036	Common Stock	8,542	$0	8,542	D

Explanation of Responses:

1. Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Incyte (INCY) executive Matteo Trotta report on this Form 4?

Matteo Trotta, EVP and GM of Dermatology US at Incyte Corporation, reported receiving an employee stock option grant on the companys common stock on January 16, 2026.

How many Incyte (INCY) stock options were granted to Matteo Trotta?

The filing shows that 8,542 employee stock options were granted to Matteo Trotta, giving him the right to buy an equal number of Incyte common shares.

What is the exercise price and expiration date of Matteo Trottas Incyte stock options?

The employee stock options have an exercise price of $106.21 per share and an expiration date of January 15, 2036, as disclosed in the derivative securities table.

How do the Incyte (INCY) stock options granted to Matteo Trotta vest?

According to the footnote, beginning January 16, 2026, the options vest in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the next three years.

What is Matteo Trottas position and relationship to Incyte (INCY)?

The reporting person, Matteo Trotta, is listed as an officer of Incyte Corporation with the title EVP, GM, Dermatology US, and is not identified as a director or 10% owner.

How many derivative securities does Matteo Trotta hold after this Incyte option grant?

After the reported transaction, Matteo Trotta beneficially owns 8,542 derivative securities, all held directly as employee stock options on Incyte common stock.